Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Fred Dotzler
AddedMar 31, 2024
UpdatedMay 31, 2026
Fred Dotzler

Fred Dotzler

Board Member, Bayhill Therapeutics

Crunchbase

Fred Dotzler's Career

Bayhill Therapeutics
Bayhill Therapeutics

Portola Valley, CA, US

Board Member· Board
Astute Medical
Astute Medical

San Diego, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Fred Dotzler's Career

Bayhill Therapeutics
Bayhill Therapeutics
Series A$61.2M752000Portola Valley, CA, US
Board Member· Board

Leadership at Bayhill Therapeutics

Hideki GarrenHideki GarrenCo-Founder
Lawrence SteinmanLawrence SteinmanCo-Founder
John Peter WalkerJohn Peter WalkerCEO
David J CollierDavid J CollierBoard Member
Dr John J SavareseDr John J SavareseBoard Member
Dr Rosina Maar PaviaDr Rosina Maar PaviaBoard Member

Similar to Bayhill Therapeutics

BlossomHill TherapeuticsBlossomHill TherapeuticsSan Diego, CA, USDrug Developmentest. 2020BlossomHill TherapeuticsSan Diego, CA, US · est. 2020

BlossomHill Therapeutics: A biopharma firm innovating in oncology and autoimmune disorder treatments.

Late Stage Private · $161.6M22
Marillion PharmaceuticalsMarillion PharmaceuticalsExton, PA, USDrugs, Therapeuticsest. 2005Marillion PharmaceuticalsExton, PA, US · est. 2005

Marillion Pharmaceuticals: Innovating and commercializing therapeutics for cancer and autoimmune diseases across the US.

Public · $500k5
Nuon TherapeuticsNuon TherapeuticsSan Mateo, CA, USTherapiesest. 2002Nuon TherapeuticsSan Mateo, CA, US · est. 2002

Nuon Therapeutics: A US-based biotech firm innovating therapies for autoimmune and inflammatory diseases.

Series A · $48M75
Halia TherapeuticsHalia TherapeuticsSalt Lake City, UT, USTherapeuticsest. 2017Halia TherapeuticsSalt Lake City, UT, US · est. 2017

Halia Therapeutics: Preclinical biopharma firm innovating therapies for inflammatory and neurological disorders.

Series C · $47.2M11
Astute Medical
Astute Medical
Acquired$209.1M02007San Diego, CA, US
Board Member· Board

Leadership at Astute Medical

Phil GutryPhil GutryBoard Member
Jim BlairJim BlairBoard Member
David DouglassDavid DouglassBoard Member
Paul McPhersonPaul McPhersonBoard Member
Chris HibberdChris HibberdBoard Member
Kim D. BlickenstaffKim D. BlickenstaffBoard Member

Fred Dotzler's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Fred Dotzler

Rolf ClassonRolf ClassonBoard Member · Fresenius Medical CareJames W YoungJames W YoungBoard Member · Portal InstrumentsMark RotheraMark RotheraCEO · Viracta TherapeuticsDouglas FallerDouglas FallerBoard Member · Viracta TherapeuticsChuck SwobodaChuck SwobodaBoard Member · Vast TherapeuticsMichael SchmertzlerMichael SchmertzlerBoard Member · PTC Therapeutics